Spero Therapeutics (SPRO) EPS (Basic) Growth (5y) (2021 - 2026)
Powered by 
Analysis
Spero Therapeutics (SPRO) EPS (Basic) Growth (5y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.60 Bn | 192.61 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.45 Bn | 176.27 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.43 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.58 Bn | 73.59 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.66 Bn | 55.48 Bn | 1.37 Bn |
| 6 | Moderna | 53.76 Bn | 48.63 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.39 Bn | 30.08 Bn | 992.69 Mn |
| 8 | Biogen | 31.86 Bn | 30.58 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.09 Bn | 29.09 Bn | 1.16 Mn |
| 10 | Spero Therapeutics | 66.66 Mn | 15.89 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.34% |
| Mar 31, 2026 | 28.14% |
| Dec 31, 2025 | 21.41% |
| Sep 30, 2025 | 31.44% |
| Jun 30, 2025 | 49.11% |
| Mar 31, 2025 | 26.34% |
| Dec 31, 2024 | 23.21% |
| Sep 30, 2024 | 19.05% |
| Jun 30, 2024 | 15.13% |
| Mar 31, 2024 | 5.69% |
| Dec 31, 2023 | 28.23% |
| Sep 30, 2023 | 36.71% |
| Jun 30, 2023 | 20.03% |
| Mar 31, 2023 | 19.36% |
| Dec 31, 2022 | 16.27% |
| Sep 30, 2022 | 60.99% |
| Jun 30, 2022 | 53.50% |
| Mar 31, 2022 | 46.76% |
| Dec 31, 2021 | 49.37% |
| Sep 30, 2021 | 50.39% |